Background: Recently, two randomized controlled trials demonstrated the benefit of mechanical thrombectomy performed between 6 and 24 h in acute ischemic stroke. The current economic evidence is supporting the intervention only within 6 h, but extended thrombectomy treatment times may result in better long-term outcomes for a larger cohort of patients.
Introduction
Stroke is a global health issue and continues to be a leading cause of mortality and disability worldwide. 1, 2 A number of prospective randomized trials published in 2015 showed mechanical thrombectomy (MT) is safe and effective in the management of ischemic stroke within 6 h of symptom onset. [3] [4] [5] [6] [7] Published evidence has shown it is also cost-effective. [8] [9] [10] [11] [12] [13] The precedent to transform stroke management was therefore set. Some of the 2015 endovascular therapy studies suggested further benefits beyond this time window. Specifically, REVASCAT and ESCAPE actively recruited beyond the 6-h window with encouraging, but not definitive safety and efficacy outcomes. 5, 6 This suggestion is now more certain with two prospective randomized controlled trials recently demonstrating that thrombectomy plus standard medical therapy (SMT) for ischemic stroke at 6 to 16 h (DEFUSE 3) and 6 to 24 h (DAWN) results in a better functional outcomes at 90 days than SMT alone. 14, 15 Previous economic evaluations of thrombectomy undertaken in the UK have been based on the evidence supporting endovascular intervention only within 6 h. 8, 9 Clinical encounters do not always conform to these time-frames and the recent evidence shows extending thrombectomy treatment times may result in better long term outcomes for this cohort.
Aims
We investigated the cost-utility of MT in the acute management of stroke with symptom onset between 6 and 24 h in the UK, using the results of the DAWN and DEFUSE 3 trials.
Methods
We undertook a cost-utility analysis to compare costs and outcomes of MT following SMT compared to SMT alone in patients with acute ischemic stroke. We used the data from the DEFUSE 3 trial to estimate the cost-utility of MT at 16 h, and the data from the DAWN trial to estimate the cost-utility of MT at 12 and 24 h. The outcome measure was quality-adjusted life years (QALYs), which combine length of life and quality of life, based on National Institute for Health and Care Excellence (NICE) recommendations. 16 The number of deaths averted was also reported as an additional outcome measure. The cost-effectiveness of MT was expressed in terms of its Incremental Cost Effectiveness Ratio (ICER), compared to the current medical therapy. The analysis took a UK National Health Service (NHS) and personal social services (PSS) perspective. Costs were calculated in 2017 UK£, inflated where necessary and presented in US$ using an exchange rate of £1 ¼ US$1.28. [17] [18] [19] The time horizon was 20 years, reflecting the average life expectancy of the patients treated in both trials. All costs and outcomes after the first year were discounted at an annual rate of 3.5%. 16 
Model structure
We considered two treatment options: SMT alone (which includes intravenous tissue plasminogen activator (IV-tPA)) versus SMT followed by MT. Outcomes in both options were based on modified-Rankin-Scale (mRS) scores measured at 90 days after stroke, which were assumed to be affected by recanalization rates.
A short-run decision analytical model (Figure 1(a) ) was created to assess costs and clinical outcomes within three months from stroke and subsequently was utilized to distribute a theoretical cohort of patients into one of three possible health states. A long-run Markov statetransition model was then used to estimate the expected costs and outcomes over a lifetime horizon of 20 years using cycles of three months (Figure 1(b) ).
We populated the model with data from the DEFUSE 3 trial to estimate the cost-utility at 16 h and from the DAWN trial to estimate the costeffectiveness at 12 and 24 h (Supplementary Table 1 ). In doing so, we took into account the different treatments provided and the different type of devices used for the thrombectomy and outcomes.
Costs
A micro-costing approach was used to calculate the cost of the two treatment options pathways.
The cost of medical therapy was estimated to be $2346 (£1819), including the cost of the IV-tPA medication and administration (Supplementary Tables 2  and 3 ). 20, 21 Staff time costs were estimated using the data on the average cost per hour. 17 The cost of the thrombectomy varied in each trial: it was estimated to be $8320 (£6486) for the DEFUSE 3 trial (where a stentriever was used in 80% of cases), and $6339 (£4942) in the DAWN trial (where a Trevo Õ stentriever was used for all the MT interventions). This includes the cost of the devices, materials and intervention (Supplementary Table 3 ).
The health care costs in the first three months after stroke and the ongoing costs in the following years differ according to disability (mRS score). The acute management costs include length of stay in the Hyper Acute Stroke Unit, in the acute High Dependency Unit, and in the rehabilitation ward, as well as the supported discharge cost and community care costs. 8, 17, 21 We estimated the cost of a recurrent stroke as the mean expected cost to treat an average stroke that does not need SMT or MT.
Outcomes
Outcomes were expressed in QALYs, which combine length of life and quality of life. 16 These were measured starting from the mRS score in which are categorized the patients affected by stroke: independent (mRS score 2), dependent (mRS score 3-5) or dead (mRS ¼ 6). 22 For each mRS score we used the most updated and reliable values available in the literature that take into account the EuroQol elicitation method (Supplementary Table 2 ). 21, [23] [24] [25] Other sources were used for the sensitivity analyses. 26, 27 
Probabilities
We used the data provided in the two trials to calculate the probability of being independent, dependent or dead at 90 days in each treatment arm. 14, 15 For the following months we applied the transition probabilities in Supplementary Table 2 , transformed for cycles of three months. We assumed that the probability of having a recurrent stroke was the same for a patient coming from an independent or a dependent state. Patients could move between a dependent and independent state only in the first year, but thereafter they were assumed to remain in that state, have a recurrent stroke or die. Patients who survived another stroke could either die or move into a dependent state, or remain independent. 23, 28 Measuring cost-effectiveness Cost-effectiveness of MT plus SMT compared to SMT alone was measured in terms of the incremental cost per QALY gained (ICER). We also report the Net Monetary Benefits (NMB), calculated as the mean QALYs per patient accruing to that treatment multiplied by the maximum willingness to pay (WTP) for a QALY (the cost-effectiveness threshold) minus the mean cost per patient for the treatment. The lower and upper limit of the maximum WTP for a QALY are $33,000 (£20,000) and $49,500 (£30,000) respectively in the UK. 16 
Sensitivity analysis
Extensive sensitivity analyses were performed, incuding a probabilistic sensitivity analysis (PSA) to determine the impact of the uncertainty surrounding the model input parameters. 16 The distributions assigned to each parameter value are described in Supplementary  Table 2 . A random value from the corresponding distribution was selected. This generated an estimate of the mean cost and mean QALY and the NMB associated with each treatment. This was repeated 10,000 times and the results for each simulation were noted. The proportion of times either treatment had the highest NMB was calculated for a range of values of the WTP for a QALY. The results are summarized using costeffectiveness acceptability curves (CEACs). The mean International Journal of Stroke, 15 (1) cost, QALYs and NMB for each treatment were calculated from the 10,000 simulations; these are probabilistic results (Figure 3 and Supplementary Table 4 ).
Results
Using plus SMT was higher than the NMB of SMT alone at both the lower and upper limits of the maximum WTP for a QALY, indicating that this option was preferred on cost-effectiveness ground. The PSA confirms the main results (Supplementary Table 4 ).
The cost-effectiveness acceptability curves for the two interventions show that MT had 99.9% probability of being cost-effective at the lower and upper values of the maximum WTP for QALY commonly used in UK (Figures 2 and 3) .
The results of the one-way sensitivity analysis showed that the cost of thrombectomy must exceed $42,563 (£33,185) using the DEFUSE 3 trial data at 16 h for the intervention to become borderline cost-effective for the lower value of the maximum WTP for QALY. Similarly, it must exceed $45,555 (£35,518) and $55,331 (£43,140) using the DAWN trial data at 12 and 24 h respectively to no longer be cost-effective.
Discussion
Previous evidence demonstrated the cost-effectiveness of MT compared to SMT alone within a 6-h timeframe from symptom onset. This study not only validates those results, but also suggests that performing thrombectomy beyond this time frame and up to 24 h after stroke symptom onset remains cost-effective.
The 2015 publications of concordant evidence supporting the use of thrombectomy up to 6 h after symptom onset resulted in a paradigm shift in the modern management of acute stroke. Subsequently, MT is being performed more frequently, with decreasing costs due to economies of scale (discounts in devices purchased and more efficient interventions). Two of the initial seminal trials, REVASCAT and ESCAPE, recruited up to 8 and 12 h respectively. 5, 6 This additional data was indicative that the 6 hour mark was likely to be a conservative estimate. By combining data from the 5 big trials, the Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) collaborative confirmed that thrombectomy was effective up to 7.3 h after symptoms onset. 29 DAWN and DEFUSE 3 have further added to this evidence demonstrating significant benefit with thrombectomy beyond 6 h, which was contributed to by the higher recanalization rate.
An important point to note is the methodology was variable between trials, which makes the formulation of consistent inclusion criteria challenging. However, extrapolating trial parameters to actual population cohorts is necessary when assessing the likely impact any change in practice will deliver. Vanacker et al. 30 showed the sub-6 hour endovascular intervention would benefit 10% of people presenting with acute ischemic stroke symptoms. Subsequently, Jadhav et al. 31 applied DAWN and DEFUSE 3 criteria to a similar cohort and 1.7-2.7% of patients would be eligible for >6 h MT based on these criteria. This suggests that despite variation in methods, an applicable inclusion model could be formulated.
Between April 2015 and March 2016, health and social care costs related to stroke exceeded £1.7 billion in England, Wales and Northern Ireland. 32 Despite MT having an initial higher cost, it leads to savings downstream in the stroke care pathway due to better outcomes. Between April 2016 and March 2017, 85,122 new cases of stroke were registered in the UK; of these 74,585 (87.6%) were ischemic strokes and 9898 had thrombolysis. 33 Despite 11,188 patients meeting the < 6-h eligibility for thrombectomy, only 580 patients (5%) were treated. 33 It is not known how many of those remaining patients could have been treated with thrombectomy between 6 and 24 h, but assuming this figure is also 5%, we estimate around 3287 additional patients could have thrombectomy for an incremental budgetary impact of $8. To the best of our knowledge, this is the first study in the UK that assesses the cost-utility of MT performed beyond 6 h from symptom onset. The advantage of this study is that we have used data from randomized controlled trials using thrombectomy specifically looking at the 6 to 24 hour treatment window. These studies focused on anterior circulation events. There remains a paucity of randomized controlled trial evidence looking at posterior circulation events.
The analysis has some limitations. In the DEFUSE 3 trial, patients were treated with different devices. For this analysis, we assumed all used the Solitaire TM device, being the most widely accessed stentriever 34 and coincidentally one of the more expensive device options. This assumption, therefore, may actually overestimate the costs of thrombectomy. We also assumed all patients underwent perfusion imaging in both arms. We did not analyze the etiology of the stroke or associated risk factors that the studies mention (i.e. hypertension, diabetes, atrial fibrillation (AF), prior stroke), because numbers were very similar in both cohorts (with the exception of AF) and would essentially negate each other. Furthermore, the data for an accurate analysis was not available and beyond the scope of this study. In the DAWN trial, 5% of patients in the intervention arm had IV-tPA compared to 13% in the control arm, therefore the cost has been weighted accordingly. Finally, we assumed dependent and independent patients have the same probability of having a recurrent stroke, although one may expect this probability to be higher among the more disabled. The results of our sensitivity analysis showed that our conclusions were not sensitive to this assumption.
This study was undertaken from the perspective of the UK NHS and did not include societal costs. Given that the incidence of stroke in patients under 60 years of age has increased by more than 4% in the last three years, 33 it is likely that the cost savings attributable to MT would be greater than demonstrated if we could take into account productivity losses and societal costs.
We have demonstrated that thrombectomy performed between 6 and 24 h after symptom onset is cost-effective, based on current data. These results, combined with the recent trial data would make a valuable contribution to reforming acute stroke service models.
